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Background: Clinical factors determining short-term survival after pancreatectomy have been well studied, but
factors predicting long-term survival with curative resection are poorly understood in pancreatic carcinoma. Our
objective was to identify clinical and pathological features of five-year disease-free survivors after surgical resection
of pancreatic adenocarcinoma.
Methods: The clinical and pathological data from 147 patients who underwent a potentially curative resection for
pancreatic adenocarcinoma at our institution between 1988 and 2012 were retrospectively analyzed.
Results: Of 147 patients, 18 survived for more than five years after surgery without disease recurrence. A univariate
analyses demonstrated that: two or fewer lymph node metastases (P = 0.014), a preoperative serum carbohydrate
antigen 19-9 (CA19-9) level of 40 U/mL or less (P = 0.0018), an absence of intrapancreatic nerve invasion (P = 0.028),
and undergoing an R0 resection (P = 0.011) were significantly associated with five-year survival. A logistic regression
model identified the following independent cancer-related predictors of five-year survivors: having two or fewer
lymph node metastases (odds ratio (OR): 6.02; 95% confidence interval (CI): 1.08 to 112.98; P = 0.0385), a
preoperative serum CA19-9 level of 40 U/mL or less (OR: 5.02; 95% CI: 1.68 to 16.48; P = 0.0036), and undergoing an
R0 resection (OR: 3.63; 95% CI: 1.12 to 14.28; P = 0.0316).
Conclusions: We conclude that number of lymph node metastases being two or less, a preoperative serum CA19-9
level of 40 U/mL or less, and undergoing an R0 resection may be independent predictive factors to identify actual
five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
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Pancreatic carcinoma is the fourth leading cause of death
from cancer and is responsible for 43,000 deaths per year
in the United States [1]. The prevalence of pancreatic can-
cer in Japan has also increased in the last decade to be-
come the fifth leading cause of cancer death in men, and
the sixth in women [2]. This malignancy is devastating,
with a five-year overall survival rate of approximately 5%
[1]. The only potentially curative treatment for pancreatic
cancer is surgical resection. However, only a small number* Correspondence: kenjiro@med.osaka-cu.ac.jp
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unless otherwise stated.of patients (between 15 and 20%) present with a resectable
tumor at the time of diagnosis [3]. Moreover, the progno-
sis even after potentially curative resection is considered
to be poor. The following characteristics have been repor-
ted to be significant prognostic factors for patient survival
after tumor resection: age [4], tumor size [4-6], lymph
node metastasis [4-6], surgical margin status [7-9], pre-
operative serum CA19-9 level [9-11], and tumor grade [7].
Clinical factors determining short-term survival after pan-
createctomy have been well studied, but prognostic factors
predicting long-term survival with curative resection are
poorly understood [12-14].
In the earlier studies, it was difficult to discuss fac-
tors related to five-year survival because of the highLtd. This is an Open Access article distributed under the terms of the Creative
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can be performed safely, and the postoperative mortality
in some specialized pancreatic centers is reported to be
less than 5% [15-17]. In the many previous reports, the
follow-up period was within five years, but precise data on
the long-term survival and prognostic factors can be ob-
tained by analysis not only of actuarial data, but also of
data of patients who achieve actual long-term survival of
five years or more.
The aim of this study was to identify the clinical and
pathological features of five-year survivors after surgical
resection of pancreatic ductal carcinoma. This study
could aid oncologists and surgeons in determining which
characteristics or clinicopathological factors suggest an
increased possibility of five-year survival after pancreatic
resection for pancreatic carcinoma.
Methods
Patients
A total of 195 patients who underwent pancreatectomy
for pancreatic ductal carcinoma at our institution bet-
ween January 1988 and October 2012 were studied. In-
formed consent was obtained from all patients to use
the specimens for this study according to the institutional
rules of the hospital. All patients were histologically con-
firmed to have the common type of invasive ductal carci-
noma of the pancreas. Any patients with neuroendocrine
carcinoma, mucinous cystic carcinomas, or intraductal pa-
pillary mucinous carcinomas were excluded. Of the 195
patients, 48 patients were excluded for the following rea-
sons: 42 censored cases, composed of four patients who
were lost to follow-up during the observation period and
38 patients who were alive within five years after the oper-
ation; four due to postoperative mortality within 30 days;
and two were five-year survivors with recurrence disease.
The data from the remaining 147 patients, who were five-
year survivors without disease recurrence (five-year survi-
vors) and died within five years after surgery (short-term
survivors), was retrospectively analyzed. The demographic
and clinical variables included age, sex, preoperative se-
rum CA19-9 level, and tumor location. In patients with
preoperative jaundice, the data after the jaundice was re-
duced was used as the preoperative serum CA19-9 values.
In patients with jaundice at our medical center, endo-
scopic or percutaneous bile duct drainage is usually per-
formed. The CA19-9 value in all patients was the value
after total bilirubin was reduced to under 5 mg/dL. All pa-
tients had presented with resectable localized disease
without distant metastasis. None of the patients received
neoadjuvant therapy before surgery. Fourteen patients had
intraoperative radiation therapy (IORT), and 20 patients
received adjuvant chemotherapy with gemcitabine. All pa-
tients were followed up on for survival, and the median
follow-up period was 14.5 (2.1 to 170.2) months.Surgery and pathology
Surgery involved standard or subtotal stomach-preserving
pancreaticoduodenectomy in 90 patients (61.2%), distal
pancreatectomy in 49 (33.3%), and total pancreatectomy
in eight (5.4%). Regional lymph node dissection was per-
formed in all patients and the median number of resected
lymph nodes was 24 (range: 2 to 100). The resected speci-
mens were fixed in 10% formalin at room temperature,
and the size and gross appearance of the tumor were
recorded. The pathologic stage of all tumor specimens
was determined using the American Joint Committee
on Cancer (Sixth edition) staging system [18]. Tumor dif-
ferentiation was classified according to the World Health
Organization’s classification of either well-differentiated
(Grade 1), moderately differentiated (Grade 2), poorly dif-
ferentiated (Grade 3), or undifferentiated (Grade 4) [19].
A positive margin was defined as the presence of at least
one cancer cell within 1 mm of one or more resection
margins on a macroscopic examination. The pathological
features that might affect prognosis were histologically
assessed tumor size, serosal invasion (S), retroperiton-
eal tissue invasion (RP), intrapancreatic common bile
duct invasion (CH), portal vein invasion (PV), lymph
node metastasis, lymphatic invasion (LY), venous inva-
sion (V), and intrapancreatic nerve invasion (NE), on
the basis of the Japan Pancreas Society classification
(Sixth edition) [20].
Statistical analysis
The clinicopathological features were compared between
five-year survivors and short-term survivors. The risk
factors related to survival were examined in long-term
survivors. Categorical variables were compared using the
χ2 test or Fisher’s exact test. A receiver operating charac-
teristics (ROC) curve was constructed to estimate the
optimal cutoff value of preoperative serum CA19-9. The
cutoff value was determined as the point closest to the
upper left-hand corner of the graph. Variables with a sig-
nificance of P <0.05 on a univariate analysis were in-
cluded in a multivariate regression analysis to identify
factors associated with long-term survival. Survival was
calculated using the Kaplan-Meier method and compared
between groups by the log-rank test. P values <0.05 were
considered significant. Statistical analyses were performed
using SAS version 9.0 software (SAS Institute, Inc., Cary,
North Carolina, United States).
Results
Characteristics of patient and tumor-related data of these
147 patients are given in Table 1. The median overall
survival of all cases was 14.4 months; short-term and
five-year survivors were 12 months and 125.6 months,
respectively. The actuarial three- and five-year survival
rates were 18.4% and 12.2%, respectively. The median



































Figure 1 Receiver operating characteristic (ROC) curve analysis
of preoperative CA19-9 for prediction of five-year survival of
patients with pancreatic carcinoma. An ROC curve demonstrated
that a preoperative serum CA19-9 level of 40 U/mL was the optimal
cutoff point. The area under the curve (AUC) was 0.670.
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on between 19888 and 2000) and late cases (2001 to
2012) were 13.5 and 14.7 months, respectively. There
are no statistical differences in survival (P = 0.65).
The median preoperative serum CA19-9 level of the 147
patients was 122 U/mL. An ROC curve demonstrated that
a preoperative serum CA19-9 level of 40 U/mL was the
optimal cutoff point for five-year survival, with a sensitiv-
ity of 66.7% and a specificity of 73.6%. The area under the
curve (AUC) was 0.670 (Figure 1).
Of the 147 patients, 18 patients (12.2%) survived more
than five years after surgery without disease recurrence.
The median age of five-year survivors (13 men, five
women) was 65 years (range: 46 to 76). The distributionof the tumor stages according to The UICC TNM Classifi-
cation (UICC (Union for International Cancer Control)
Sixth) was: stage IA (n = 1; 5.6%); IB (n = 2; 11.1%); IIA
(n = 6; 33.3%); IIB (n = 9; 50%); and stage III or IV
(none). The pancreatic resections were standard pan-
creaticoduodenectomy in 12 patients and distal pan-
createctomy in six patients. The median tumor size was
32 mm (range: 12 to 55), including five patients (27.8%)
with tumor diameters of 20 mm or less. Eight patients
were positive for lymph node metastasis, and all patients
with positive lymph nodes had within two positive lymph
nodes. Portal vein resection was performed in two pa-
tients, and R0 surgery was performed in 14 (77.8%) pa-
tients. Tumor recurrences beyond five years after surgery
were observed in four patients. The longest time for recur-
rence was 8.4 years after surgery (Table 2).
Table 3 shows the results of the univariate analysis of
the factors affecting five-year survival after pancreatec-
tomy in the 147 patients. Sex, age, tumor location, tumor
size, histologic differentiation, T classification, N classifica-
tion, adjuvant therapy, S, RP, CH, LY, V, portal vein resec-
tion, and IORT were evaluated, but were not significant
on univariate analysis. Significant associations with five-
year survival were observed for number of lymph node
metastases being two or less (P = 0.014), a preoperative
serum CA19-9 level cutoff of 40 U/mL (P = 0.0018), the
absence of NE (P = 0.028), and undergoing an R0 resection
(P = 0.011).
A logistic regression model adjusted for two or fewer
lymph node metastases, a preoperative serum CA19-9














71/F 2 Pb 16 IA 0 0 DP 0 68/A None
76/F 65 Ph 30 IIB 1 2 PD 0 69/D None
72/M 597 Pt 40 IIB 1 2 DP 1 73/D Dissemination
57/M 611 Ph 42 IIB 0 0 PD with PV 0 74/A None
73/F 3221 Pbt 32 IIB 1 2 DP 0 78/A None
76/M 21 Ph 20 IIA 0 0 PD 0 79/D None
62/M 103 Ph 40 IIB 1 2 PD 0 85/D Lymph node
61/M 29 Ph 12 IIA 0 0 PD 1 86/A None
46/M 31 Ph 40 IIA 0 0 PD 0 89/D Liver/local
68/F 2381 Ph 55 IIA 0 0 PD 0 92/A None
73/M 39 Pb 38 IIB 1 1 DP 0 100/A None
60/F 34 Ph 50 IIB 1 2 PD 0 108/A None
70/M 29 Ph 32 IB 0 0 PD 0 111/A None
57/M 20 Ph 30 IIB 1 2 PD with PV 1 122/D Lung/skin
56/M 4.1 Ph 20 IIA 0 0 PD 0 129/D None
57/M 30 Pb 30 IB 0 0 DP 0 144/A None
57/M 7 Pb 35 IIA 0 0 DP 0 145/A None
70/M 2 Ph 15 IIB 1 1 PD 1 170/A None
A, alive; D, dead; DP, distal pancreatectomy; Pb, body of the pancreas; Pbt, body and tail of the pancreas; PD, pancreaticoduodenectomy; Ph, head of the
pancreas; Pt, tail of the pancreas; PV, portal vein resection; R, resection status.
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the absence of NE identified the following independent
cancer-related predictors of five-year survivors: two or
fewer lymph node metastases, (OR: 6.02, 95% CI: 1.08 to
112.98; P = 0.0385), CA19-9 ≤ 40 U/mL (OR: 5.02; 95% CI:
1.68 to 16.48; P = 0.036), and R0 resection (OR: 3.63;
95% CI: 1.12 to 14.28; P = 0.0316) (Table 4).
On the basis of the multivariate analysis results, a com-
bined analysis of the preoperative serum CA19-9 level, R0
resection, and number of lymph node metastases being
two or less was performed. When each of the three pre-
dictors was counted as one point and the points were cal-
culated for all 147 cases, a good stratified survival curve
was obtained, showing the longer survival in the higher
points: median survival times of three, two, one, and zero
points were 39.0, 17.0, 8.2, and 8.6 months, respectively
(P <0.0001) (Figure 2).
Discussion
The present study identified three factors (number of
lymph node metastases being two or less, preoperative
serum CA19-9 level of ≤40 U/mL, and R0 resection), as
being related to five-year survival after surgical resection
of pancreatic ductal carcinoma. Moreover, the longest
survival time was observed in patients who had all of
these three factors (Figure 2). To date, prognostic factors
for pancreatic carcinoma have been vigorously investi-
gated [4-11]. However, the present study did not simply
examine prognostic factors; instead, by analyzing patientswho actually achieved five-year survival, factors for five-
year survival were more accurately identified.
Tumor size has been considered an important prog-
nostic factor for pancreatic cancer. Large surgical series
showed that five-year survival rate (20 to 41%) and me-
dian survival time (23 to 38 months) of small pancreatic
cancer were better than the five-year survival rate (1 to
20%) and median survival time (10 to 17 months) of
large pancreatic cancer [5,21-24]. In the present study,
small pancreatic cancer (≤2 cm) was not a factor related
to five-year survival after surgical resection for pancre-
atic cancer on univariate analysis. About a quarter of pa-
tients surviving for more than five years had tumors 2
cm or smaller, suggesting that even patients with a larger
tumor can achieve five-year survival.
There are many reports that lymph node metastases
are a prognostic factor [4-6]. In addition, the number of
positive lymph nodes divided by the total number of
lymph nodes evaluated (LNR) has also been reported as
a prognostic factor [8]. However, there are few reports
limited to the number of lymph nodes. Huebner et al.
reported new findings on predictive factors for five-year
survival when dividing patients into groups with ≤1 ver-
sus ≥2 lymph node metastases [25]. In the present study,
actual five-year survivors were limited to patients with
two or few lymph node metastases. This result suggested
that three or more lymph node metastases may mean
that lymph node metastases exist outside the area of dis-
section, or that distal metastases may be present.
Table 3 Univariate analysis of factors affecting five-year










Male 72 13 0.21
Female 57 5
Age (years)
Median (range) 67 (33-85) 65 (46-76) 0.28
Tumor location
Head 85 12 1
Body/tail 44 6
Tumor size (cm)
Median (range) 3.5 (1.2-18) 3.2 (1.2-5.5) 0.52
≤2 cm 14 5 0.06
>2 cm 115 13
Histologic differentiation
Grade 1-2 102 11 0.13
Grade 3-4 27 7
T classification
T1-T2 14 3 0.44
T3-T4 115 15
N classification
N0 49 10 0.2
N1 80 8
Number of resected lymph nodes
Median (range) 25 (2100) 17 (258) 0.51
Number of lymph node
metastasis
≤2 95 18 0.01
≥3 34 0
CA19-9 level (U/mL)
Median (range) 172 (223009) 30.5 (23221) 0.02
≤40 34 12 0
>40 94 6
Resection margin
R0 58 14 0.01
R1-R2 71 4
Adjuvant therapy
Yes 19 1 0.47
No 110 17
Serosal invasion
Present 81 10 0.61
Absent 48 8
Retroperitoneal invasion
Present 91 11 0.58
Absent 36 6
Table 3 Univariate analysis of factors affecting five-year




Present 61 7 0.62
Absent 68 11
Lymphatic permeation
Present 113 16 1
Absent 16 2
Vascular permeation
Present 63 8 0.8
Absent 66 10
Intrapancreatic nerve invasion
Present 118 13 0.03
Absent 13 5
Portal vein resection
Present 31 2 0.37
Absent 98 16
Intraoperative radiation therapy
Present 11 3 0.38
Absent 118 15
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was established using ROC curve analysis as described in
the statistical section. The AUC of 0.67 at the cutoff value
may be statistically insufficient for sensitivity and specifi-
city, however, it was optimal in our data. Abnormally ele-
vated CA19-9 levels have been reported as a prognostic
factor in previous studies, but the cutoff values have
ranged widely from 30 to 1,000 U/mL. The normal value
for CA19-9 is ≤37 U/mL, and interestingly, a CA19-9
of ≤40 U/mL (near the normal value) was associated withTable 4 Multivariate analysis of factors affecting five-year







Number of lymph node metastasis
≤2 6.02 1.08-112.98 0.0385
≥3 1
CA-19-9 level (U/mL)
≤40 5.02 1.68-16.48 0.0036
>40 1
Resection margin
R0 3.63 1.12-14.28 0.0316
R1-R2 1
Intrapancreatic perineural invasion
Absent 2.72 0.645-10.86 0.1664
Present 1
Figure 2 A combined analysis of the preoperative serum CA19-9 level, R0 resection, and number of lymph node metastases being two
or less. The subgroup of preoperative serum CA19-9≤ 40 U/mL and R0 resection, together with number of lymph node metastases ≤2, is
associated with a probability of five-year survival of 42.1%. MST, median survival time.
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ported cutoff values of 28 U/mL or 30 U/mL in terms
of prognosis, which supports the current results [9].
These results might suggest that long-term survival
after surgical resection for pancreatic ductal carcinoma
requires that the preoperative CA19-9 level be around
the normal range. No other tumor markers, including
CEA (Carcinoembryonic antigen) and DUPAN-2, were
useful as prognostic indicators (data not shown).
Resection status has also been often reported as a
prognostic factor. The present study also found residual
tumor status to be an independent predictive factor re-
lated to five-year survival. On the other hand, retroperi-
toneal invasion was not a predictive factor for five-year
survival. This important finding means that, even in
cases with retroperitoneal invasion, R0 resection is im-
portant and hopeful for five-year survival.
In addition, four patients had tumor recurrence be-
yond five years of follow-up. The longest interval to re-
currence was 8.7 years, with lung and skin metastases.
Therefore, it should be kept in mind during the follow-
up period that recurrences may occur even after five
years. Schnelldorfer et al. reported that none of the 30
patients who survived beyond 7.8 years had recurrence
of disease, and all survived beyond 10 years [6]. Katz et al.
also reported that late recurrence after five years occurredin seven patients and the latest cancer-related death oc-
curred at 7.6 years [26]. In consideration of our report and
the previous reports, survival beyond 10 years might sug-
gest a potential cure.
The CONKO-001 trial [27] reported gemcitabine to be
effective as a postoperative adjuvant therapy. This trial
reported that treatment with adjuvant gemcitabine led
to a 24% improvement in overall survival, with a signifi-
cant 10.3 percentage point absolute improvement in the
five-year overall survival rate (20.7 versus 10.4%), com-
pared with observation alone. Moreover, a recent phase
three study compared S-1 and gemcitabine as postopera-
tive adjuvant therapy and reported S-1 to be superior. In
this study, in the S-1 therapy group, median relapse-free
survival time was 23.2 months, and the two-year relapse-
free survival rate was 49% [28]. These results strongly
suggest that adjuvant chemotherapy achieved long-term
survival after surgical resection. However, in the present
study a small number of 20 patients received gemcitabine
as adjuvant therapy, resulting in no impact of adjuvant
therapy on the survival time (Table 3). Since gemcitabine
and S-1 have been recently recognized as standard adju-
vant therapies after pancreatectomy for pancreatic cancer
with the above mentioned evidences [27,28], the rate of
adjuvant therapy using either of the two drugs has grad-
ually increased in Japan. Nowadays more than 80% of the
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S-1 after pancreatectomy in our institution. With increas-
ing use of adjuvant therapy for pancreatic cancer in the fu-
ture, five-year survivors would be expected to increase.
Although neoadjuvant chemotherapy and neoadjuvant
chemoradiotherapy for pancreatic cancer have been inves-
tigated for last two decades, their survival benefit has still
not been proven [29,30]. At our institution, neoadjuvant
chemoradiotherapy with gemcitabine and S-1 have been
used since 2013 for unresectable and borderline resectable
pancreatic adenocarcinoma. In our series, some initially
unresectable cases have been resectable. But several years
are needed to evaluate whether neoadjuvant chemoradio-
therapy will become a prognostic factor or not.
Using the predictive model, the subgroup of preopera-
tive serum CA19-9 level cutoff of 40 U/mL and R0 re-
section, together with number of lymph node metastases
being two or less, is associated with a probability of five-
year survival of 42.1% (Figure 2). Although long-term
survival in this subgroup can be strongly expected, R0
resection and two or fewer lymph node metastases were
post-resection parameters. This result suggests that pa-
tients not expected to have these factors at the time of
preoperative diagnosis should have neoadjuvant treat-
ment or stronger adjuvant chemotherapy.
The limitations of the present study are as follows.
This was a retrospective study conducted at a single in-
stitution. Approximately 5 to 10% of the general popula-
tion is Lewis antigen A and B-negative, which means
that they do not synthesize the CA19-9 antigen and will
not have elevated levels, even with pancreatic cancer or
other malignancies. In the present series, the data re-
lated to Lewis antigens A and B could not be included
because of the retrospective nature of the study.Conclusions
In conclusion, the present study showed that two or fewer
lymph node metastases, a preoperative serum CA19-9
level of 40 U/mL or less, and R0 resection were associ-
ated with five-year disease-free survival of patients with
pancreatic cancer who underwent surgical resection.
Patients with these three factors are expected to have a
high five-year survival rate after surgical resection of
pancreatic carcinoma.
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